Hologic’s (HOLX) “Outperform” Rating Reiterated at William Blair

William Blair reissued their outperform rating on shares of Hologic (NASDAQ:HOLX) in a research report report published on Monday,RTT News reports.

A number of other brokerages have also commented on HOLX. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Needham & Company LLC reissued a “buy” rating and set a $90.00 target price on shares of Hologic in a research report on Monday. BNP Paribas upgraded shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Mizuho cut their price target on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Finally, Wolfe Research assumed coverage on Hologic in a report on Friday, December 13th. They set a “peer perform” rating for the company. Seven analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus price target of $88.92.

Hologic Trading Down 2.1 %

NASDAQ HOLX opened at $68.75 on Monday. Hologic has a one year low of $68.61 and a one year high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The business has a 50 day simple moving average of $75.44 and a 200 day simple moving average of $78.50. The stock has a market capitalization of $15.60 billion, a P/E ratio of 20.65, a P/E/G ratio of 2.44 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the prior year, the business earned $0.89 earnings per share. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. Research analysts expect that Hologic will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.75% of the company’s stock.

Institutional Trading of Hologic

Large investors have recently added to or reduced their stakes in the stock. Benson Investment Management Company Inc. bought a new position in shares of Hologic during the 4th quarter valued at approximately $4,832,000. GAMMA Investing LLC lifted its stake in Hologic by 17.9% in the third quarter. GAMMA Investing LLC now owns 3,832 shares of the medical equipment provider’s stock valued at $312,000 after purchasing an additional 582 shares during the last quarter. Clean Yield Group lifted its stake in Hologic by 18.9% in the fourth quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider’s stock valued at $3,291,000 after purchasing an additional 7,266 shares during the last quarter. Janus Henderson Group PLC grew its holdings in Hologic by 2.9% during the third quarter. Janus Henderson Group PLC now owns 28,776 shares of the medical equipment provider’s stock valued at $2,344,000 after purchasing an additional 800 shares during the period. Finally, Versor Investments LP purchased a new stake in Hologic in the third quarter worth $1,677,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.